HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (3,5- bis(trifluoromethyl)phenyl)- 2- chloro- 4- (trifluoromethyl)pyrimidine- 5- carboxamide

transcription factor inhibitor specific to T-cells

Also Known As:

SP 100030; SP-100030; SP100030

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide: 5

Experts

1.	Argilés, Josep M: 2 articles (04/2009 - 05/2007)
2.	Busquets, Sílvia: 2 articles (04/2009 - 05/2007)
3.	López-Soriano, Francisco J: 2 articles (04/2009 - 05/2007)
4.	Moore-Carrasco, Rodrigo: 2 articles (04/2009 - 05/2007)
5.	Palanki, Moorthy: 2 articles (04/2009 - 05/2007)
6.	Figueras, Maite: 1 article (04/2009)
7.	Adachi, Yukihiko: 1 article (12/2007)
8.	Bruno, Nelson E: 1 article (12/2007)
9.	D'Alessandro-Gabazza, Corina N: 1 article (12/2007)
10.	Erdman, Paul E: 1 article (12/2007)

Related Diseases

1.	Fibrosis (Cirrhosis) 12/15/2007 - "The inhibitory activity of SP100030 was dose dependent and was effective in acute and chronic phases of lung fibrosis. " 12/15/2007 - "The effect of SP100030 was evaluated using a mouse model of chronic lung fibrosis. " 12/15/2007 - "We assessed the potential therapeutic effect of SP100030, a specific inhibitor of T-cell NF-kappaB and AP-1 in lung fibrosis. "
2.	Arthritis (Polyarthritis) 08/01/2000 - "beginning on day 21) significantly decreased arthritis severity from onset of clinical signs to the end of the study on day 34 (arthritis score, 5.6 +/- 1.7 for SP100030 and 9.8 +/- 1.5 for control; p < 0.001). "
3.	Hepatocellular Carcinoma (Hepatoma) 04/01/2009 - "Daily treatment of rats bearing Yoshida AH-130 ascites hepatoma with the nuclear factor kappa-B (NF-kappaB) and activator protein-1 (AP-1) double inhibitors SP100030 and SP100207 at a dose of 5 mg/kg and 10 mg/kg of body weight, respectively, resulted in a clear inhibition of tumour growth. " 05/01/2007 - "Daily treatment of rats bearing the cachectic Yoshida AH-130 ascites hepatoma with the double inhibitor of NF-kappaB and AP-1 SP100030 at a dose of 1 mg/kg of body weight resulted in a clear amelioration of the cachectic effect, especially at the level of skeletal muscle. "
4.	Cachexia 05/01/2007 - "The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia." 12/15/2007 - "Mice treated with SP100030, as compared with untreated mice, had significantly less cachexia and less lung injury and had decreased levels of inflammatory cytokines and growth factors, decreased activation of coagulation activation, and decreased collagen deposition in the lung. "
5.	Body Weight (Weight, Body) 04/01/2009 - "Daily treatment of rats bearing Yoshida AH-130 ascites hepatoma with the nuclear factor kappa-B (NF-kappaB) and activator protein-1 (AP-1) double inhibitors SP100030 and SP100207 at a dose of 5 mg/kg and 10 mg/kg of body weight, respectively, resulted in a clear inhibition of tumour growth. " 05/01/2007 - "Daily treatment of rats bearing the cachectic Yoshida AH-130 ascites hepatoma with the double inhibitor of NF-kappaB and AP-1 SP100030 at a dose of 1 mg/kg of body weight resulted in a clear amelioration of the cachectic effect, especially at the level of skeletal muscle. "

Related Drugs and Biologics

1.	NF-kappa B (NF-kB)
2.	Transcription Factor AP-1 (Transcription Factor AP 1)
3.	Cytokines
4.	Therapeutic Uses
5.	Intercellular Signaling Peptides and Proteins (Growth Factors)
6.	Transcription Factors (Transcription Factor)
7.	Messenger RNA (mRNA)
8.	Collagen
9.	Allergens